Drug news
GLOW 1 and GLOW 3 studies to support SeebriBreezhaler application.
The GLOW 1 and GLOW 3 studies show that investigational NVA237 (glycopyrronium bromide)from Novartis significantly increased patients' lung function compared to placebo with a fast onset of action at first dose, as well as improving exercise endurance. NVA237 is a new drug in the long-acting anti-muscarinic (LAMA) class which has recently been submitted for approval in the European Union under the brand-name Seebri Breezhaler. Novartis plan to file the drug as monotherapy and in combination with indacaterol (Onbrez BreezHaler ).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins